Financial Performance - The total assets of the company as of September 30, 2025, amounted to 657.33 million, reflecting a 1.49% increase compared to the previous year [5] - The net profit attributable to shareholders for the first nine months of 2025 was 20.71 million, a decrease of 4.36% from 21.65 million in the same period of 2024 [5] - The operating revenue for the first nine months of 2025 was 114.17 million, representing a growth of 5.04% compared to 108.70 million in the previous year [5] Key Financial Ratios - The asset-liability ratio for the parent company increased to 10.06% from 9.91% year-on-year [5] - The weighted average return on equity based on net profit attributable to shareholders was 3.82%, down from 4.08% in the previous year [5] Cash Flow Analysis - The net cash flow from operating activities for the first nine months of 2025 was 22.54 million, a decline of 3.06% from 23.25 million in the same period of 2024 [5] - The cash flow from investment activities showed a significant decrease of 131.51%, amounting to -13.98 million, primarily due to increased financial investments compared to the previous year [6] Shareholder Structure - The total number of shares outstanding remained at 91.52 million, with 59.86% being unrestricted shares [9] - The largest shareholder, Zhou Fang, holds 24.47% of the shares, while the second-largest shareholder, Xiao Changxi, holds 15.83% [11] Major Events - The company reported no significant legal disputes or external guarantees during the reporting period [15] - There were no pledges or judicial freezes on shares held by major shareholders [12]
收入涨5%：新芝生物发布Q3财报